TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10204735
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg pethidine (P100)
Study: 10204735
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg pethidine (P200)
Study: 28983938
Drug: Moisturizing skincare
Normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moisturizing skincare (bathing every 2 days and using lotion daily)
Study: 28983938
Drug: Daily bathing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily bathing without lotion (control)
Study: 27657522
Drug: ICS/LABA combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS/LABA combination
Study: 27657522
Drug: ICS monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS monotherapy
Study: 15758763
Drug: Pentosan polysulfate
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan polysulfate sodium (PPS) 300 mg, 3 times daily
Study: 8864316
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg orally)
Study: 6594157
Drug: Extra-amniotic infusion
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-amniotic infusion of prostaglandin E2 (PGE2)
Study: 3514164
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of prednisone daily for 2 weeks
Study: 3514164
Drug: Baseline spirometric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline spirometric data and beta‐agonist responsiveness
Study: 27874299
Drug: TACO (immersion
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACO (immersion in 151 L of 2.1°C ± 0.8°C water)
Study: 24780728
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g dried plum/d
Study: 24780728
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g dried apple/d (comparative control)
Study: 23248893
Drug: Multi-directional power
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-directional power toothbrush (Oral-B Vitality TriZone)
Study: 20447049
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTA) injection combined with 10 sessions of physical and occupational therapy followed by 10 sessions of neuromuscular electrical stimulation on the wrist extensors
Study: 15733028
Drug: Combined sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined sequential HRT
Study: 6363155
Drug: Arginine thiazolidinecarboxylate
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine thiazolidinecarboxylate (800 mg/day for 40 days)
Study: 31489424
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral health education
Study: 31489424
Drug: Routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oral hygiene education (Control)
Study: 20519079
Drug: Yitongshu injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yitongshu injection (4 ml) into the Zusanli point on both sides 11 hours or 23 hours after administration of the drugs.
Study: 17425758
Drug: Amlodipine-enalapril combination
Normalized name: enalapril / felodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine-enalapril combination
Study: 15781019
Drug: Docosahexaenoic acid
Normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docosahexaenoic acid (1.2 g/day for 6 weeks)
Study: 10809859
Drug: Hypericum ointment
Normalized name: Hypericum oil
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum ointment
Study: 6433319
Drug: Heparin (1
Normalized name: 2,3-o-Desulfated heparin (12000 da)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (1 U/mL) added to intravenous alimentation solutions
Study: 782146
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no heparin)
Study: 31053295
Drug: Serum antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum antibodies to neuronal proteins
Study: 28685542
Drug: Continuous blood
Normalized name: Dexcom G6 Receiver Continuous Blood-Glucose M
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous blood purification (CBP) in addition to conventional therapy
Study: 26158927
Drug: HSM‐IOL (heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSM‐IOL (heparin surface modified intraocular lens)
Study: 23384411
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of human umbilical tissue-derived cells (hUTC) into the nucleus pulposus (NP)
Study: 23384411
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of hydrogel carrier alone
Study: 23384411
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of human umbilical tissue-derived cells (hUTC) with hydrogel carrier
Study: 23384411
Drug: Punctured group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Punctured group (no treatment)
Study: 21740403
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy as an adjunct to pharmacological therapy
Study: 21740403
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard pharmacological therapy only)
Study: 18505387
Drug: AmB, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmB, 1 mg/kg per day, plus flucytosine, 25 mg/kg 4 times per day (group 2)
Study: 18505387
Drug: AmB, 0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmB, 0.7 mg/kg per day, plus flucytosine, 25 mg/kg 4 times per day (group 1)
Study: 17063641
Drug: Thyme-ivy combination
Normalized name: THYME
DrugBank: Thyme (DB10983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyme-ivy combination syrup (5.4 ml three times daily for 11 days)
Study: 17063641
Drug: Thyme-ivy combination
Normalized name: THYME
DrugBank: Thyme (DB10983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyme-ivy combination syrup
Study: 17063641
Drug: Thyme-ivy combination
Normalized name: THYME
DrugBank: Thyme (DB10983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyme-ivy combination syrup and Placebo syrup
Study: 12953167
Drug: Low-dose radioiodine-131
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radioiodine-131 (131I) treatment (141 +/- 85 MBq)
Study: 10782840
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose rhGH (12 IU/m2/week)
Study: 10782840
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose rhGH (24 IU/m2/week)
Study: 9324342
Drug: CVPP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVPP chemotherapy (3 cycles)
Study: 9324342
Drug: CVPP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVPP chemotherapy (6 cycles)
Study: 9324342
Drug: CVPP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVPP chemotherapy (6 cycles) + Radiotherapy (RT)
Study: 9324342
Drug: AOPE chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AOPE chemotherapy (6 cycles) + Radiotherapy (RT)
Study: 9324342
Drug: CCOPP/CAPTe chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCOPP/CAPTe chemotherapy (6 cycles)
Study: 8223808
Drug: Acetaminophen administered
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen administered at regular 4h intervals (group 1)
Study: 8223808
Drug: Sporadic usage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sporadic usage of acetaminophen contingent upon a body temperature above 37.9 degrees C (group 2)
Study: 8223808
Drug: Sporadic usage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sporadic usage of acetaminophen (group 2)
Study: 3950253
Drug: Terbutaline (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (0.25 mg per puff)
Study: 30075954
Drug: Oestradiol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol 1.5 mg/day for 6 months
Study: 30075954
Drug: Testosterone 50
Normalized name: testosterone 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone 50 mg/day for 6 months
Study: 24909487
Drug: Magnesium oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium oxide 450 mg up to three times daily
Study: 18316791
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment arms
Study: 17220631
Drug: Oral orlistat
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral orlistat
Study: 8784758
Drug: Aspirin (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1.3 g) before running
Study: 8784758
Drug: Aspirin (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1.3 g) before rest
Study: 7930385
Drug: Normal subjects
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal subjects rendered mildly hyperglycemic by a 24-h glucose infusion (1 mg/kg/min for NDT and 2 mg/kg/min for IGT)
Study: 21838913
Drug: Selenium micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium micronutrient supplement
Study: 15294856
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (screening and treatment for infection)
Study: 9602986
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg daily, at night)
Study: 9602986
Drug: Sucralfate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (2 g twice daily)
Study: 2403809
Drug: Surgery and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery and steroids
Study: 359215
Drug: Trimazosin 100
Normalized name: trimazosin
DrugBank: Trimazosin (DB09206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimazosin 100 to 300 mg
Study: 26581750
Drug: High-dose esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose esomeprazole (80 mg + 8 mg/h)
Study: 26581750
Drug: Cimetidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (200 mg + 60 mg/h)
Study: 24232362
Drug: Structured exercise
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured exercise program (weekly supervised gym sessions of stationary cycling and resistance exercises, and a twice weekly independent home-based walking program)
Study: 19274317
Drug: Weekly doses
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly doses of 25 mg of elemental iron administered at home
Study: 19274317
Drug: Weekly doses
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly doses of 25 mg of elemental iron administered in healthcare clinic
Study: 14535968
Drug: Hyperglycaemia (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycaemia (15 mmol L(‐1))
Study: 2029860
Drug: Tramadol 150
Normalized name: traMADol 150 mg/24 hours oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 150 mg
Study: 2029860
Drug: Tramadol 300
Normalized name: TRAMADOL 300MG (RYZOLT) SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 300 mg
Study: 9589267
Drug: Morphine 15
Normalized name: morphine 15 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 15 mg
Study: 3829579
Drug: Morphine 30
Normalized name: ethylmorphine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 30 mg
Study: 27812636
Drug: Gel pillow
Normalized name: Willow bark
DrugBank: Willow bark (DB14691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel pillow with side cutouts
Study: 17379047
Drug: VAL/HCTZ 320/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAL/HCTZ 320/25 mg
Study: 10190880
Drug: Tyramine administration
Normalized name: tyramine
DrugBank: Tyramine (DB08841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyramine administration
Study: 15305962
Drug: Isoproterenol administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol administration
Study: 27164015
Drug: Phenylephrine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine administration
Study: 11422018
Drug: Bisoprolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (5 mg)
Study: 11527135
Drug: Atenolol and
Normalized name: atenolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol and Bisoprolol (both beta1-selective beta-blockers)
Study: 6127907
Drug: Anti-anxiety drugs
Normalized name: INVESTIGATIONAL ANTI-ANXIETY DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-anxiety drugs (including clorazepate and diazepam)
Study: 30588277
Drug: Telerehabilitation (TR)
Normalized name: hyoscyamine sulfate Extended Release Oral Tablet [Hyoscyamine TR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telerehabilitation (TR) treatment
Study: 30588277
Drug: In-person (IP)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-person (IP) treatment
Study: 27771799
Drug: Salbutamol (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (1000 µg)
Study: 24253140
Drug: Balanced solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced solution of 6% hydroxyethyl starch (Plasma Volume Redibag)
Study: 15704613
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 20 mg rabeprazole
Study: 15704613
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 20 mg rabeprazole
Study: 15704613
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (oral and intravenous)
Study: 1780994
Drug: Chloroquine phosphate
Normalized name: Chloroquine Phosphate
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine phosphate 2500 mg over 3 days
Study: 1780994
Drug: Chloroquine prophylaxis
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine prophylaxis 500 mg weekly for 27 weeks
Study: 1780994
Drug: Chloroquine prophylaxis
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine prophylaxis 500 mg weekly for 27 weeks after nodulectomy and acute malaria treatment
Study: 11928797
Drug: Surgical and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical and chemotherapeutic treatment
Study: 31926827
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist luteal support 0.1 mg SC every other day, starting on day 3 post egg retrieval
Study: 31926827
Drug: 80 Âµg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 Âµg recombinant hCG (Ovitrelle, Merck Serono SA) as control, single dose on day 3 post-egg retrieval
Study: 25899956
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 mg orally twice a day for 4 days (10 doses total)
Study: 24306214
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein diet (NPD) - 1.2 g protein ⋅ kg body weight(‐1) ⋅ d(‐1)
Study: 24306214
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein diet (LPD) - 0.1 g protein ⋅ kg body weight(‐1) ⋅ d(‐1)
Study: 11524347
Drug: Parecoxib Sodium
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib Sodium 20 mg IV
Study: 11524347
Drug: Parecoxib Sodium
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib Sodium 40 mg IV
Study: 11524347
Drug: Parecoxib Sodium
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib Sodium 80 mg IV
Study: 9930595
Drug: Loratadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (10 mg daily p.o.)
Study: 8039123
Drug: Ocular ice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular ice pack therapy
Study: 28291957
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (40IU)
Study: 23345639
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 to 600 mg/d
Study: 18066566
Drug: RAL (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAL (60 mg daily and continuously)
Study: 18066566
Drug: HRT (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (2 mg estradiol valerat + 2 mg dienogest, continuously)
Study: 1735849
Drug: Synthetic surfactant
Normalized name: Synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue
DrugBank: CHF5633 (DB18696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic surfactant (Exosurf Neonatal) 5 ml/kg
Study: 1993961
Drug: Air (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air (control group) 5 ml/kg
Study: 6501237
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg yohimbine hydrochloride
Study: 6501237
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg yohimbine hydrochloride
Study: 27055606
Drug: Jet injection
Normalized name: Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet injection of lidocaine
Study: 22503057
Drug: Drug-eluting balloon
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting balloon (DEB) plus bare-metal stent (BMS)
Study: 11115952
Drug: Poor effort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poor effort to take medication
Study: 23791061
Drug: HTK solution
Normalized name: Custodial HTK Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTK solution
Study: 1352564
Drug: EuroCollins solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: EuroCollins solution
Study: 4030486
Drug: Hyaluronidase added
Normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hyaluronidase added to retrobulbar anesthetic injection
Study: 4030486
Drug: Topical indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical indomethacin before surgery and for nine months postoperatively
Study: 29083477
Drug: Intranasal birch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal birch pollen allergen Bet v 1
Study: 29083477
Drug: Intranasal omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal omalizumab
Study: 29083477
Drug: Subcutaneous omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous omalizumab
Study: 26906034
Drug: Anakinra 100
Normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra 100 mg twice daily for 3 days followed by once daily for 11 days
Study: 20556260
Drug: Mucosa-supported implant-retained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucosa-supported implant-retained overdenture (OD) with an ovoid bar (two implants; design 1)
Study: 20556260
Drug: Mucosa-supported implant-retained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucosa-supported implant-retained overdenture (OD) with multiple ovoid bars (four implants; design 2)
Study: 20556260
Drug: Rigid implant-supported
Normalized name: Pinus rigida pollen
DrugBank: Pinus rigida pollen (DB10896)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rigid implant-supported prosthesis (ISP) with a milled bar (design 3)
Study: 18391103
Drug: eGFR <40
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR <40 mL/min
Study: 18391103
Drug: eGFR 40
Normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR 40 to 60 mL/min
Study: 18391103
Drug: eGFR >60
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR >60 mL/min
Study: 15826311
Drug: Estrogen‐progestogen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen‐progestogen therapy
Study: 15826311
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or no drugs
Study: 12516831
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EMD and GTR using a collagen membrane
Study: 12516831
Drug: GTR monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTR monotherapy
Study: 12516831
Drug: EMD monotherapy
Normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMD monotherapy
Study: 1743444
Drug: High-dose dipyridamole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dipyridamole echocardiography test (DET: 2D-echo monitoring during dipyridamole infusion up to 0.84 mg/kg over 10 minutes)
Study: 1743444
Drug: High-dose dipyridamole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dipyridamole echocardiography test (DET)
Study: 9603590
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg bromazepam
Study: 31050201
Drug: Prucalopride 2
Normalized name: prucalopride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride 2 mg plus 45 mL NaP (P-NaP)
Study: 31050201
Drug: 90 mL
Normalized name: 190 ML Infugem 10 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mL NaP in two split doses (90-NaP)
Study: 27886382
Drug: Cucumis sativus
Normalized name: CUCUMIS SATIVUS LEAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cucumis sativus seed extract (500 mg daily for 6 weeks)